NCAPH promotes proliferation as well as motility of breast cancer cells by activating the PI3K/AKT pathway

Zhang, Ting; Guo, Wanying; Liu, Qipeng; Qiao, Weiqiang; Deng, Miao

doi:10.1556/2060.2022.00028

Cited by 3 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Except for the role of ERFE in genomics and chromosomes, our study also identified co-expression of ERFE and IL-11 , a known activator of PI3K-AKT and mTOR signaling pathways [ 43 , 44 ]. In addition, NCAPH expression was also reported to accelerate the tumor progression via PI3K-AKT signaling [ 45 , 46 ]. The activation of a core cancer regulating PI3K-AKT pathway was further validated by GSEA analysis in nine types of tumors in this study.…”

Section: Discussionmentioning

confidence: 99%

In Silico Pan-Cancer Analysis Reveals Prognostic Role of the Erythroferrone (ERFE) Gene in Human Malignancies

Altrock

Schmitt

et al. 2023

IJMS

View full text Add to dashboard Cite

The erythroferrone gene (ERFE), also termed CTRP15, belongs to the C1q tumor necrosis factor-related protein (CTRP) family. Despite multiple reports about the involvement of CTRPs in cancer, the role of ERFE in cancer progression is largely unknown. We previously found that ERFE was upregulated in erythroid progenitors in myelodysplastic syndromes and strongly predicted overall survival. To understand the potential molecular interactions and identify cues for further functional investigation and the prognostic impact of ERFE in other malignancies, we performed a pan-cancer in silico analysis utilizing the Cancer Genome Atlas datasets. Our analysis shows that the ERFE mRNA is significantly overexpressed in 22 tumors and affects the prognosis in 11 cancer types. In certain tumors such as breast cancer and adrenocortical carcinoma, ERFE overexpression has been associated with the presence of oncogenic mutations and a higher tumor mutational burden. The expression of ERFE is co-regulated with the factors and pathways involved in cancer progression and metastasis, including activated pathways of the cell cycle, extracellular matrix/tumor microenvironment, G protein-coupled receptor, NOTCH, WNT, and PI3 kinase-AKT. Moreover, ERFE expression influences intratumoral immune cell infiltration. Conclusively, ERFE is aberrantly expressed in pan-cancer and can potentially function as a prognostic biomarker based on its putative functions during tumorigenesis and tumor development.

show abstract

Section: Discussionmentioning

confidence: 99%

In Silico Pan-Cancer Analysis Reveals Prognostic Role of the Erythroferrone (ERFE) Gene in Human Malignancies

Altrock

Schmitt

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…The PI3K pathway has emerged as a key player in BC development [ 6 , 7 ]. The PI3K pathway governs a wide range of cellular processes through its signaling mechanism, such as cell growth [ 8 , 9 ], survival [ 10 , 11 ], metabolism [ 8 , 12 ] and motility [ 13 ]. Dysregulation of the PI3K pathway is linked with several aspects of BC development and progression [ 14 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway

Tufail,

Hu,

Liang

et al. 2024

J Transl Med

View full text Add to dashboard Cite

Breast cancer (BC) is a multifaceted disease characterized by distinct molecular subtypes and varying responses to treatment. In BC, the phosphatidylinositol 3-kinase (PI3K) pathway has emerged as a crucial contributor to the development, advancement, and resistance to treatment. This review article explores the implications of the PI3K pathway in predictive, preventive, and personalized medicine for BC. It emphasizes the identification of predictive biomarkers, such as PIK3CA mutations, and the utility of molecular profiling in guiding treatment decisions. The review also discusses the potential of targeting the PI3K pathway for preventive strategies and the customization of therapy based on tumor stage, molecular subtypes, and genetic alterations. Overcoming resistance to PI3K inhibitors and exploring combination therapies are addressed as important considerations. While this field holds promise in improving patient outcomes, further research and clinical trials are needed to validate these approaches and translate them into clinical practice. Graphical Abstract

show abstract

NCAPH serves as a prognostic factor and promotes the tumor progression in glioma through PI3K/AKT signaling pathway

Liang,

Yun,

Jin

et al. 2024

Mol Cell Biochem

View full text Add to dashboard Cite

Non-SMC (Structural Maintenance of Chromosomes) condensin I complex subunit H (NCAPH) has been shown to facilitate progression and predict adverse prognostic outcome in many cancer types. However, the function of NCAPH in gliomas is still unclear. Series of experiments were taken to uncover the function of NCAPH in glioma. The expression of NCAPH and potential mechanism regulating progression of glioma was verified by bioinformatics analysis. Lentiviral transfection was used for establishment of loss-of-function and gain-of-function cell lines. CCK-8 assay and Colony-formation assay were used to evaluate proliferation. Transwell assay and Cell wound healing assay were used to assess migration and invasion. Cell cycle and apoptosis were measured by flow cytometry. Protein and RNA were quantified by WB and RT-PCR, respectively. The nude mice model of glioma was used to evaluate the effect of NCAPH in vivo. The expression of NCAPH increased significantly in glioma tissues and correlated with WHO grade, IDH wild-type and non-1p/19q codeletion. Glioma patients with high expression of NCAPH had an undesirable prognosis. Functionally, upregulated NCAPH promotes the malignant hallmarks of glioma cells in vivo and in vitro. NCAPH correlated with DNA damage repair ability of glioma cells and facilitated the proliferation, invasion, and migration of glioma cells by promoting the PI3K/AKT signaling pathway. This study identifies the important pro-tumor role of NCAPH in glioma and suggests that NCAPH is a potential therapeutic target.

show abstract

NCAPH promotes proliferation as well as motility of breast cancer cells by activating the PI3K/AKT pathway

Cited by 3 publications

References 24 publications

In Silico Pan-Cancer Analysis Reveals Prognostic Role of the Erythroferrone (ERFE) Gene in Human Malignancies

In Silico Pan-Cancer Analysis Reveals Prognostic Role of the Erythroferrone (ERFE) Gene in Human Malignancies

Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway

NCAPH serves as a prognostic factor and promotes the tumor progression in glioma through PI3K/AKT signaling pathway

Contact Info

Product

Resources

About